Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity

Open Interest and Volume Dynamics

The open interest (OI) in Zydus Lifesciences’ futures and options contracts jumped from 16,741 to 24,091 contracts, an increase of 7,350 contracts or 43.9% on the day. This sharp rise in OI was accompanied by a total volume of 59,822 contracts traded, indicating robust participation from derivatives traders. The futures segment alone accounted for a value of approximately ₹51,590 lakhs, while the options segment’s notional value was substantially higher at ₹45,625 crores, underscoring the prominence of options activity in the stock’s derivatives market.

The underlying stock price closed at ₹920, having touched an intraday high of ₹933.35, up 5.09% from the previous close. This price action outperformed the Pharmaceuticals & Biotechnology sector, which gained 1.56%, and the broader Sensex, which rose 0.58% on the same day. The stock’s 1-day return of 3.97% also surpassed the sector’s performance by 2.23%, signalling relative strength in the short term.

Market Positioning and Directional Bets

The surge in open interest alongside rising prices typically suggests fresh long positions being initiated, reflecting bullish sentiment among derivatives traders. However, the weighted average price of traded contracts was closer to the day’s low, indicating that a significant volume of trades occurred near lower price levels. This could imply cautious accumulation or hedging activity rather than an outright aggressive directional bet.

Further, the stock’s moving averages present a nuanced picture. It is trading above its 5-day, 20-day, and 50-day moving averages, which supports a short-term positive trend. Yet, it remains below the 100-day and 200-day moving averages, signalling that the longer-term trend is still under pressure. This divergence often attracts speculative interest in the near term but warrants caution for investors seeking sustained momentum.

Investor participation in the cash segment has shown signs of moderation. Delivery volume on 6 Feb was 2.72 lakh shares but has declined by 16.22% compared to the 5-day average delivery volume, suggesting that while derivatives activity is heating up, actual stock holding by investors is tapering off. This divergence between derivatives and cash market participation can sometimes precede volatility or a change in trend direction.

Fundamental and Technical Assessment

Zydus Lifesciences, a mid-cap pharmaceutical and biotechnology company with a market capitalisation of ₹89,203 crore, has recently seen its Mojo Grade downgraded from Hold to Sell as of 1 Dec 2025. The current Mojo Score of 43.0 reflects a cautious stance based on a combination of financial metrics, price trends, and market sentiment.

The downgrade was influenced by factors such as slowing investor participation in the cash segment and the stock’s inability to decisively break above its longer-term moving averages. While the recent price rally and open interest surge indicate short-term optimism, the overall quality grades and market cap grade of 2 suggest limited upside potential relative to peers.

Liquidity remains adequate, with the stock’s traded value supporting a trade size of approximately ₹1.08 crore based on 2% of the 5-day average traded value. This ensures that institutional and retail investors can transact without significant price impact, which is crucial for derivatives market stability.

Implications for Investors and Traders

The sharp increase in open interest combined with rising prices often signals that traders are positioning for a potential upward move. However, the mixed signals from volume-weighted average price and moving averages suggest that this rally may be tentative. Investors should be wary of possible volatility as the market digests these developments.

Options activity, given its large notional value, may be reflecting hedging strategies or complex directional bets such as spreads or straddles. This complexity can sometimes mask the true directional bias, making it essential for investors to monitor changes in put-call ratios and strike-wise open interest for clearer insights.

Given the current Sell rating and the downgrade from Hold, long-term investors may prefer to wait for confirmation of a sustained uptrend before increasing exposure. Conversely, short-term traders might exploit the heightened volatility and open interest surge for tactical trades, keeping tight risk management in place.

Conclusion: Navigating the Derivatives Surge

The recent surge in open interest for Zydus Lifesciences Ltd highlights a renewed focus on the stock within the derivatives market, driven by a combination of short-term bullishness and strategic positioning. While the stock’s outperformance relative to its sector and the Sensex is encouraging, the downgrade to a Sell rating and mixed technical indicators counsel prudence.

Investors should closely monitor evolving volume patterns, open interest changes, and price action around key moving averages to gauge whether this momentum can be sustained. For now, the derivatives market activity suggests a market in flux, with participants hedging their bets amid uncertainty about the stock’s near-term trajectory.

As always, a balanced approach combining fundamental analysis with technical signals will be essential for making informed decisions in this dynamic environment.

Unlock special upgrade rates for a limited period. Start Saving Now →